

## FOI 24/055 - MHRA FOIA Request -Clindamycin 150mg/ml, solution for injection

FOILicensing <FOILicensing@mhra.gov.uk>

Wed 07/02/2024 09:39

To [REDACTED]

### FOI 24/055

Dear [REDACTED]

Many thanks for your email dated 18 January 2024 in which you requested for the Public Assessment reports of the following products:

Clindamycin 150mg/ml, solution for injection for PL number PL 05448/0008 & PL 00057/0959

Please find our response to your request below:

[PL 05448/0008 Clindamycin 150mg/ml, solution for injection](#)

A marketing authorisation was granted in UK for Clindamycin 150mg/ml, solution for injection on 6 February 2008. A subsequent change of ownership procedure took place on 16 December 2021 from the original marketing authorisation holder (MAH); Villerton Invest SA (PL 24780/0002) to the current MAH; Istituto Biochimico Italiano G. Lorenzini SpA.

The published PAR for this product can be found on the MHRA website using the original PL number at following link [Microsoft Word - UKPAR for Clindamycin 150mg-ml Solution for Injection PL 24780-0002.doc \(windows.net\)](#).

[PL 00057/0959 Clindamycin 150mg/ml, solution for injection](#)

A marketing authorisation was granted in UK for Clindamycin 150mg/ml, solution for injection on 27 December 1990. A subsequent change of ownership procedure took place on 17 March 2014 from the original marketing authorisation holder (MAH); Pharmacia Limited (PL 00032/0042R) to the current MAH; Pfizer Limited.

As this marketing authorisation was granted before it was a legal requirement to prepare PARs for new medicinal products, no PAR has been published for this.

We now consider this response closed. If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask us to review our actions and decisions by writing to: [info@mhra.gov.uk](mailto:info@mhra.gov.uk), and requesting an internal review. Please note that your internal review request must be in a recordable format (email, letter, audio tape etc.), and that you have 40 working days upon receipt of this letter to ask for a review. We aim to provide a full response to your review request within 20 working days of its receipt. Please quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted online via an electronic form: <https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/>

or in writing to:

Information Commissioner's Office,  
Wycliffe House,  
Water Lane,  
Wilmslow,  
Cheshire,  
SK9 5AF

Yours sincerely,  
HQA FOI Team

---

From: [REDACTED]

Sent: Thursday, January 18, 2024 9:31 AM

To: MHRA Customer Services <[MHRACustomerServices@mhra.gov.uk](mailto:MHRACustomerServices@mhra.gov.uk)>

Subject: FOI 24/055 - MHRA FOIA Request -Clindamycin 150mg/ml, solution for injection

Dear Colleagues,

Greetings from [REDACTED]

We would like to request for the Public Assessment report of the following product under the Freedom of Information Act (FOIA):

**Clindamycin 150mg/ml, solution for injection for PL number PL 05448/0008 & PL 00057/0959**

Regards,

[Redacted signature block]

[Redacted signature block]

[Redacted signature block]

[Redacted signature block]

[Redacted] This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)